104 related articles for article (PubMed ID: 37269477)
1. Reply to: "developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond".
Hatanaka T; Kakizaki S; Hiraoka A; Toyoda H; Kumada T
Hepatol Int; 2023 Oct; 17(5):1320-1321. PubMed ID: 37269477
[No Abstract] [Full Text] [Related]
2. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis.
Yang M; Pan Y; Wang W
BMC Cancer; 2023 Mar; 23(1):236. PubMed ID: 36915049
[TBL] [Abstract][Full Text] [Related]
4. Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?
Guan R; Mei J; Lin W; Deng M; Li S; Guo R
Hepatol Int; 2023 Oct; 17(5):1279-1288. PubMed ID: 37129721
[TBL] [Abstract][Full Text] [Related]
5. Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".
Scheiner B; Pinter M
J Hepatol; 2022 Aug; 77(2):576-577. PubMed ID: 35526786
[No Abstract] [Full Text] [Related]
6. Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy".
Scheiner B; Pinter M
J Hepatol; 2022 May; 76(5):1233-1234. PubMed ID: 35176440
[No Abstract] [Full Text] [Related]
7. The MAPS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with targeted therapy plus immunotherapy.
Ouyang J; Yang Y; Zhou Y; Ye F; Wang Z; Li Q; Xu Y; Li L; Zhao X; Zhang W; Zhou A; Huang Z; Wang Y; Cai J; Zhao H; Zhou J
Hepatol Int; 2023 Dec; 17(6):1519-1531. PubMed ID: 37707759
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kumada T;
Hepatol Int; 2023 Feb; 17(1):86-96. PubMed ID: 36076009
[TBL] [Abstract][Full Text] [Related]
9. The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.
Zhou HF; Yang W; Zhou WZ
J Hepatol; 2022 May; 76(5):1232-1233. PubMed ID: 35063602
[No Abstract] [Full Text] [Related]
10. [Expression and prognostic significance of cyclin kinase subunit 1 in human hepatocellular carcinoma].
Zhonghua Gan Zang Bing Za Zhi; 2015 Apr; 23(4):299-301. PubMed ID: 26427082
[No Abstract] [Full Text] [Related]
11. Reply to: 'EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma'.
Husain A; Chiu YT; Ng IO
J Hepatol; 2022 Sep; 77(3):880-882. PubMed ID: 35605743
[No Abstract] [Full Text] [Related]
12. Time to move beyond the classical prognostic systems for patients with advanced hepatocellular carcinoma undergoing Sorafenib.
Marasco G; Trevisani F;
Dig Liver Dis; 2021 Sep; 53(9):1210-1211. PubMed ID: 34052178
[No Abstract] [Full Text] [Related]
13. Authors' Reply: Prognostic Impact of Osteopenia in Patients Who Underwent Living Donor Liver Transplantation for Hepatocellular Carcinoma.
Toshima T; Yoshizumi T; Harada N; Itoh S; Mori M
World J Surg; 2020 Sep; 44(9):3184-3185. PubMed ID: 32548709
[No Abstract] [Full Text] [Related]
14. Overexpression of Pyruvate Kinase M2 in Tumor Tissues Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Zhao R; Li L; Yang J; Niu Q; Wang H; Qin X; Zhu N; Shi A
Pathol Oncol Res; 2020 Apr; 26(2):853-860. PubMed ID: 30852741
[TBL] [Abstract][Full Text] [Related]
15. Reply to 'prognostic model for patients receiving arterial-embolization for hepatocellular carcinoma: issues to consider'.
Park Y; Kim SU
Liver Int; 2016 Feb; 36(2):312. PubMed ID: 26176795
[No Abstract] [Full Text] [Related]
16. Reply to External validation of an individual prognostic calculator after trans-arterial chemo-embolization for hepatocellular carcinoma.
Cucchetti A; Cappelli A; Golfieri R
Liver Int; 2016 Aug; 36(8):1232. PubMed ID: 27403768
[No Abstract] [Full Text] [Related]
17. Identification of Mutator-Derived lncRNA Signatures of Genomic Instability for Promoting the Clinical Outcome in Hepatocellular Carcinoma.
Tang X; Miao Y; Wang J; Cai T; Yang L; Mi D
Comput Math Methods Med; 2021; 2021():1205029. PubMed ID: 34840594
[TBL] [Abstract][Full Text] [Related]
18. TMEM88, CCL14 and CLEC3B as prognostic biomarkers for prognosis and palindromia of human hepatocellular carcinoma.
Zhang X; Wan JX; Ke ZP; Wang F; Chai HX; Liu JQ
Tumour Biol; 2017 Jul; 39(7):1010428317708900. PubMed ID: 28718365
[TBL] [Abstract][Full Text] [Related]
19. Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study.
Lui TKL; Cheung KS; Leung WK
Hepatol Int; 2022 Aug; 16(4):879-891. PubMed ID: 35779202
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a Three-gene Prognostic Signature for Patients with Hepatocellular Carcinoma.
Li B; Feng W; Luo O; Xu T; Cao Y; Wu H; Yu D; Ding Y
Sci Rep; 2017 Jul; 7(1):5517. PubMed ID: 28717245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
